MMP9 and gastric cancer: Andrographolide treatment on the GC cell line SGC-7901 decreased cell survival, migration, and invasion in a dose-dependent manner by inhibiting MMP-2 and MMP-9 activity and upregulating tissue inhibitors of MMPs (TIMP-1 and TIMP-2) [83].